Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07610473
PHASE2

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Sponsor: Draig Therapeutics Ltd

View on ClinicalTrials.gov

Summary

In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.

Official title: A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

118

Start Date

2026-05

Completion Date

2027-05

Last Updated

2026-05-28

Healthy Volunteers

No

Interventions

DRUG

DT-101

DT-101

DRUG

Placebo

Placebo

Locations (2)

Draig Clinical Site

DeSoto, Texas, United States

Draig Clinical Site

Miami, Texas, United States